查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
稀少腎臟疾病市場:各適應症，各分子類型(低分子，生技藥品)，各給藥途徑，各主要地區 - 產業趨勢與全球預測，2022年～2035年
市場調查報告書
商品編碼
1162468

稀少腎臟疾病市場:各適應症，各分子類型(低分子，生技藥品)，各給藥途徑，各主要地區 - 產業趨勢與全球預測，2022年～2035年

Rare Kidney Diseases Market by Target Indications, Type of Molecule (Small Molecules and Biologics ), Route of Administration and Key Geographies : Industry Trends and Global Forecast, 2022-2035
出版日期: | 出版商: Roots Analysis | 英文 95 Pages | 商品交期: 最快1-2個工作天內

價格

本報告提供全球稀少腎臟疾病市場相關調查，市場概要，以及各適應症，各分子類型(低分子，生技藥品)，各給藥途徑，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 市場形勢

  • 稀少腎臟疾病:藥物清單
  • 稀少腎臟疾病:醫藥品開發商清單

第5章 藥物簡介

  • Benlysta
  • Cystadrops®
  • Galafold®
  • Tarpeyo®
  • Ultomiris®
  • Thiola®
  • Lupkynis™
  • Sibnayal™
  • Pegunigalsidase Alfa
  • Saphnelo™
  • Atrasentan
  • Bardoxolone Methyl
  • Crovalimab
  • Ianalumab
  • Cozaar®
  • Cosentyx®
  • Empaveli®
  • Rituxan®
  • Sparsentan
  • Iptacopan
  • Narsoplimab

第6章 企業的競爭力分析

  • 主要的調查手法與參數
  • 企業競爭力分析:生技藥品開發商(Peer Group1)
  • 企業競爭力分析:低分子開發商(Peer Group2)

第7章 夥伴關係和合作

第8章 資金籌措投資

第9章 臨床試驗分析

第10章 市場預測

  • 範圍與限制
  • 主要的假設與預測調查手法
  • 全球稀少腎臟疾病市場，2022年～2035年
  • 稀少腎臟疾病市場:各分子類型分析，2022年～2035年
  • 稀少腎臟疾病市場:各給藥途徑分析，2022～2035年
  • 稀少腎臟疾病市場:各適應症分析，2022～2035年
  • 稀少腎臟疾病市場:各地區地區，2022年～2035年

第11章 臨床的商業性魅力

第12章 案例研究

  • 規模主要的參數
  • 稀少腎臟疾病:腎臟照護供應商的清單
  • 稀少腎臟疾病:腎臟照護的優點
  • 稀少腎臟疾病:未來展望
  • 稀少腎臟疾病:最近的舉措的方法

第13章 附錄I:表格形式的資料

第14章 附錄II:公司及組織的清單

Product Code: RA100387

INTRODUCTION

The term rare kidney diseases represents around 150 different indications. It is worth highlighting that the prevalence rate of rare kidney disorders (RKD) is estimated to be 60-80 per 100,000 cases / individuals in the US and Europe. Despite their relatively low prevalence, these set of indications are believed to be one of the leading causes of renal diseases, along with diabetes and other rare genetic kidney disorders. The low disease incidence rate of such disorders, coupled to the lack of awareness among the general population, often leads to late or erroneous diagnosis. This, in turn, enables suboptimal therapeutic management, as well as compromised long-term outcomes. The aforementioned factors are some of the key reasons that are believed to be responsible for high mortality rates and severe compromise on chance of survival of a patient suffering with rare kidney disorders. It is worth mentioning that, post the onset of the COVID-19 pandemic, the treatment of patients affected with rare kidney disorders became even more challenging. This can be primarily attributed to the fact that the current treatment options for such indications are heavily reliant on regular patient visits to the hospitals or medical centers. Consequently, during the pandemic, a 30% increase in mortality rate was observed in affected patients. This increase in mortality has compelled players engaged in the pharmaceutical domain to undertake necessary research initiatives in order to identify novel drugs that can efficiently treat rare kidney disorders.

Given the complexity associated with conventional treatment options, such as dialysis, kidney transplant and biopsy, drug developers engaged in this domain have shifted their focus towards the development of drugs that can target a myriad of rare kidney disorders. It is worth highlighting that, since 2020, over seven drugs have received marketing approval for the treatment of rare kidney disorders; these are (in reverse chronological order of approval) Galafold® (Fabry disease, European Medicines Agency (EMA), 2021), Lupkynis™ (Lupus Nephritis (LN), United States Food and Drug Administration (USFDA), 2021), Sibnayal™ (distal Renal Tubular Acidosis (dRTA), EMA, 2021), Tarpeyo® (Immunoglobulin A Nephropathy (IgAN), USFDA, 2021), Benlysta® (LN, USFDA, 2020), Cystadrops® (Cystinosis, USFDA, 2020), and Ultomiris® (Atypical Hemolytic Uremic Syndrome (aHUS), Japan, 2020). Further, more than 90 candidates targeting rare kidney disorders are currently under clinical investigation, while several novel leads are being evaluated in early stages of development. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. In fact, over USD 4.5 billion has been invested in this domain since 2020. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.

SCOPE OF THE REPORT

The Rare Kidney Disorders Market - Distribution by Target Indications (IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and Others), Type of Molecule (Small Molecules and Biologics (Monoclonal Antibody, Hormone, Recombinant Protein, and Others)), Route of Administration (Oral, Intravenous, Subcutaneous, and Others) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecast, 2022-2035 report features an extensive study of the current market landscape and the likely future potential associated with the rare kidney disorders market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed executive summary of key insights captured during our research. It offers a high-level view on the current state of rare kidney disorders market and its likely evolution in the mid to long term.
  • A brief introduction to various aspects of rare kidney disorders. It includes a detailed discussion on the historical evolution and factors contributing to the treatment of rare kidney disorders. Further, it highlights various prominent target indications associated with rare kidney disorders, application of omics technology and its future perspectives.
  • A detailed overview of the current market landscape of more than 127 drug candidates that are either approved or currently under development for the treatment of various rare kidney disorders, based on several relevant parameters, such as phase of development (approved, registration, phase III, phase II, phase I, pre-clinical and discovery), target molecule (complement component 5 (C5), complement component 3 (C3), a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (BLyS), Complement Factor B, and others), route of administration (oral, intravenous, subcutaneous, and others), and target indication (complement 3 glomerulopathy (C3G), focal segmental glomerular sclerosis (FSGS), IgA nephropathy (IgAN), lupus nephritis (LN), membranous nephropathy (MN)), type of molecule (biologics and small molecules), and type of biologic (monoclonal antibody (mAb), hormone, recombinant protein, enzyme replacement therapy (ERT), gene therapy, small interfering ribonucleic acid (siRNA) molecule and others). In addition, it presents details of the companies engaged in the development of drugs targeting rare kidney disorders, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, and most active players.
  • Elaborate profiles of approved and clinical stage drugs indicated for rare kidney disorders (phase II / III or above). Each profile features an overview of the drug developer, clinical trial information related to the drug, clinical trial results, and estimated sales revenues (if available).
  • A detailed competitiveness analysis of companies engaged in the development of rare kidney disorders targeting drugs, based on their developer strength (in terms of years of experience), portfolio strength (in terms of number of drugs developed), and portfolio diversity (in terms of phase of development, target indication, and drug designation).
  • An in-depth analysis of the various collaborations and partnerships that have been inked by players engaged in the development of drugs targeting various rare kidney disorders since 2017, based on several relevant parameters, such as year of partnership, type of partnership, focus area, type of partner and regional distribution of partnerships.
  • An analysis of the funding and investments made within the domain, during the period 2016-2022, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, debt financing, grants, IPOs and other offerings), leading players (in terms of amount invested) and key investors (in terms of number of funding instances).
  • A detailed clinical trial analysis of ongoing clinical studies for the evaluation of various drug candidates targeting rare kidney disorders, based on several relevant parameters, such as trial registration year, current trial status, phase of development, key target indications, patient age, study design and key geographical regions.
  • A detailed analysis of the clinical and commercial attractiveness for drugs targeting rare kidney disorders, based on several relevant parameters, such as target patient population, dosing frequency and dose strength.
  • A case study highlighting the companies engaged in offering kidney care services, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters and target indication.

One of the key objectives of this report was to evaluate the current market size and the future potential associated with rare kidney disorders market, over the coming years. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across relevant parameters, such as [A] target indications (complement 3 glomerulopathy (C3G), FSGS, IgAN, LN, membranous nephropathy (MN)), [B] type of molecule (small molecules and biologics (monoclonal antibody, hormone, recombinant protein, and others)),[C] route of administration (oral, intravenous, subcutaneous, and others) [D] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World (RoW)). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary research. For all our projects, we have conducted interviews / surveys with various experts in this domain (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

  • Who are the leading players engaged in the development of drugs targeting rare kidney disorders?
  • Which are the key drugs being developed across early and late stages of development?
  • Who are the key players providing services related to kidney care?
  • Which are the key indications targeted by drugs indicated for rare kidney disorders?
  • What type of partnership models are commonly adopted by stakeholders engaged in this domain?
  • Who are the key investors in the domain?
  • Which regions have emerged as the key hubs for conducting clinical studies focused on rare kidney disorders?
  • How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the current state of rare kidney disorders market and its likely evolution in the mid to long term.

Chapter 3 provides a brief introduction to various aspects of rare kidney disorders. It includes a detailed discussion on the historical evolution and factors contributing to the treatment of rare kidney disorders. Further, it highlights various prominent target indications associated with rare kidney disorders, application of omics technology and its future perspectives.

Chapter 4 provides a detailed overview of the current market landscape of more than 127 drug candidates that are either approved or currently under development for the treatment of various rare kidney disorders, based on several relevant parameters, such as phase of development ( approved, registration, phase III, phase II, phase I, pre-clinical and discovery), target molecule (complement component 5 ( C5), complement component 3 (C3), a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (BLyS), Complement Factor B, and others), route of administration (oral, intravenous, subcutaneous, and others), and target indication (complement 3 glomerulopathy (C3G), FSGS, IgAN, LN, membranous nephropathy (MN)), type of molecule (biologics and small molecules), and type of biologic (monoclonal antibody (mAb), hormone, recombinant protein, enzyme replacement therapy (ERT), gene therapy, small interfering ribonucleic acid (siRNA) molecule and others). In addition, it presents details of the companies engaged in the development of drugs targeting rare kidney disorders, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, and most active players.

Chapter 5 provides detailed profiles of approved and clinical stage drugs indicated for rare kidney disorders (phase II / III or above). Each profile features an overview of the drug developer, clinical trial information related to the drug, clinical trial results, and estimated sales revenues (if available).

Chapter 6 features a detailed competitiveness analysis of companies engaged in the development of rare kidney disorders targeting drugs, based on their developer strength (in terms of years of experience), portfolio strength (in terms of number of drugs developed), and portfolio diversity (in terms of phase of development, target indication, and drug designation).

Chapter 7 features an elaborate analysis of the various collaborations and partnerships that have been inked by players engaged in the development of drugs targeting various rare kidney disorders since 2017. It includes details of deals that were / are focused on the rare kidney disorders, which were analyzed on the basis of year of partnership, type of partnership, focus area, type of partner and regional distribution of partnerships. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the rare kidney disorders. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 8 presents detailed analysis of the funding and investments made within the domain, during the period 2016-2022, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, debt financing, grants, IPOs and other offerings), leading players (in terms of amount invested) and key investors (in terms of number of funding instances).

Chapter 9 presents a detailed clinical trial analysis of ongoing clinical studies for the evaluation of various drug candidates targeting rare kidney disorders, based on several relevant parameters, such as trial registration year, current trial status, phase of development, key target indications, patient age, study design and key geographical regions.

Chapter 10 features an analysis of the clinical and commercial attractiveness for drugs targeting rare kidney disorders, based on several relevant parameters, such as target patient population, dosing frequency and dose strength

Chapter 11 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2035. It also includes future sales projections of rare kidney disorders that are either marketed or in advanced stages of clinical development (phase II/III and above). Additionally, the report features the likely distribution of the current and forecasted opportunity across relevant parameters, such as [A] target indications (complement 3 glomerulopathy (C3G), FSGS, IgAN, LN, membranous nephropathy (MN)), [B] type of molecule (small molecules and biologics (monoclonal antibody, hormone, recombinant protein, and others)),[C] route of administration (oral, intravenous, subcutaneous, and others) [D] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World (RoW)). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter 12 presents case study highlighting the companies engaged in offering kidney care services, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters and target indication.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. An Overview of Rare Kidney Disorders
  • 3.2. Key Historical Events
  • 3.3. Factors Contributing to Rare Kidney Disorders
  • 3.4. Rare Kidney Disorders: Target Indications
  • 3.5. Rare Kidney Disorders: Applications of Omics Technology
  • 3.6. Rare Kidney Disorders: Future Outlook

4. MARKET LANDSCAPE

  • 4.1. Rare Kidney Disorders: List of Drugs
    • 4.1.1. Analysis by Stage of Development
    • 4.1.2. Analysis by Target Molecule
    • 4.1.3. Analysis by Target Molecule and Route of Administration
    • 4.1.4. Analysis by Target Indication
    • 4.1.5. Analysis by Stage of Development and Target Indication
    • 4.1.6. Analysis by Type of Target Molecule
    • 4.1.7. Analysis by Stage of Development and Type of Target Molecule
  • 4.2. Rare Kidney Disorders: List of Drug Developers
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Region
    • 4.2.4. Most Active Players: Analysis by Number of Drugs

5. DRUG PROFILES

  • 5.1. Benlysta
    • 5.1.1. Company Overview
    • 5.1.2. Drug Overview
    • 5.1.3. Clinical Trial Information
    • 5.1.4. Clinical Trial Results
    • 5.1.5. Estimated Sales Revenue
  • 5.2. Cystadrops®
    • 5.2.1. Company Overview
    • 5.2.2. Drug Overview
    • 5.2.3. Clinical Trial Information
    • 5.2.4. Clinical Trial Results
    • 5.2.5. Estimated Sales Revenue
  • 5.3. Galafold®
    • 5.3.1. Company Overview
    • 5.3.2. Drug Overview
    • 5.3.3. Clinical Trial Information
    • 5.3.4. Clinical Trial Results
    • 5.3.5. Estimated Sales Revenue
  • 5.4. Tarpeyo®
    • 5.4.1. Company Overview
    • 5.4.2. Drug Overview
    • 5.4.3. Clinical Trial Information
    • 5.4.4. Clinical Trial Results
    • 5.4.5. Estimated Sales Revenue
  • 5.5. Ultomiris®
    • 5.5.1. Company Overview
    • 5.5.2. Drug Overview
    • 5.5.3. Clinical Trial Information
    • 5.5.4. Clinical Trial Results
    • 5.5.5. Estimated Sales Revenue
  • 5.6. Thiola®
    • 5.6.1. Company Overview
    • 5.6.2. Drug Overview
    • 5.6.3. Clinical Trial Information
    • 5.6.4. Clinical Trial Results
    • 5.6.5. Estimated Sales Revenue
  • 5.7. Lupkynis™
    • 5.7.1. Company Overview
    • 5.7.2. Drug Overview
    • 5.7.3. Clinical Trial Information
    • 5.7.4. Clinical Trial Results
    • 5.7.5. Estimated Sales Revenue
  • 5.8. Sibnayal™
    • 5.8.1. Company Overview
    • 5.8.2. Drug Overview
    • 5.8.3. Clinical Trial Information
    • 5.8.4. Clinical Trial Results
    • 5.8.5. Estimated Sales Revenue
  • 5.9. Pegunigalsidase Alfa
    • 5.9.1. Company Overview
    • 5.9.2. Drug Overview
    • 5.9.3. Clinical Trial Information
    • 5.9.4. Clinical Trial Results
    • 5.9.5. Estimated Sales Revenue
  • 5.10. Saphnelo™
    • 5.10.1. Company Overview
    • 5.10.2. Drug Overview
    • 5.10.3. Clinical Trial Information
    • 5.10.4. Clinical Trial Results
    • 5.10.5. Estimated Sales Revenue
  • 5.11. Atrasentan
    • 5.11.1. Company Overview
    • 5.11.2. Drug Overview
    • 5.11.3. Clinical Trial Information
    • 5.11.4. Clinical Trial Results
    • 5.11.5. Estimated Sales Revenue
  • 5.12. Bardoxolone Methyl
    • 5.12.1. Company Overview
    • 5.12.2. Drug Overview
    • 5.12.3. Clinical Trial Information
    • 5.12.4. Clinical Trial Results
    • 5.12.5. Estimated Sales Revenue
  • 5.13. Crovalimab
    • 5.13.1. Company Overview
    • 5.13.2. Drug Overview
    • 5.13.3. Clinical Trial Information
    • 5.13.4. Clinical Trial Results
    • 5.13.5. Estimated Sales Revenue
  • 5.14. Ianalumab
    • 5.14.1. Company Overview
    • 5.14.2. Drug Overview
    • 5.14.3. Clinical Trial Information
    • 5.14.4. Estimated Sales Revenue
  • 5.15. Cozaar®
    • 5.15.1. Company Overview
    • 5.15.2. Drug Overview
    • 5.15.3. Clinical Trial Information
    • 5.15.4. Clinical Trial Results
    • 5.15.5. Estimated Sales Revenue
  • 5.16. Cosentyx®
    • 5.16.1. Company Overview
    • 5.16.2. Drug Overview
    • 5.16.3. Clinical Trial Information
    • 5.16.4. Estimated Sales Revenue
  • 5.17. Empaveli®
    • 5.17.1. Company Overview
    • 5.17.2. Drug Overview
    • 5.17.3. Clinical Trial Information
    • 5.17.4. Clinical Trial Results
    • 5.17.5. Estimated Sales Revenue
  • 5.18. Rituxan®
    • 5.18.1. Company Overview
    • 5.18.2. Drug Overview
    • 5.18.3. Clinical Trial Information
    • 5.18.4. Clinical Trial Results
    • 5.18.5. Estimated Sales Revenue
  • 5.19. Sparsentan
    • 5.19.1. Company Overview
    • 5.19.2. Drug Overview
    • 5.19.3. Clinical Trial Information
    • 5.19.4. Clinical Trial Results
    • 5.19.5. Estimated Sales Revenue
  • 5.20. Iptacopan
    • 5.20.1. Company Overview
    • 5.20.2. Drug Overview
    • 5.20.3. Clinical Trial Information
    • 5.20.4. Clinical Trial Results
    • 5.20.5. Estimated Sales Revenue
  • 5.21. Narsoplimab
    • 5.21.1. Company Overview
    • 5.21.2. Drug Overview
    • 5.21.3. Clinical Trial Information
    • 5.21.4. Clinical Trial Results
    • 5.21.5. Estimated Sales Revenue

6. COMPANY COMPETITIVENESS ANALYSIS

  • 6.1. Key Methodology and Parameters
  • 6.2. Company Competitiveness Analysis: Biologic Developers (Peer Group 1)
  • 6.3. Company Competitiveness Analysis: Small Molecule Developers (Peer Group 2)

7. PARTNERSHIPS AND COLLABORATIONS

  • 7.1. Rare Kidney Disorders: List of Partnerships
  • 7.2. Analysis by Year of Partnership
  • 7.3. Analysis by Type of Partnership
  • 7.4. Analysis by Year and Type of Partnership
  • 7.5. Analysis by Type of Partnership and Company Size
  • 7.6. Analysis by Target Indication
  • 7.7. Most Active Players: Analysis by Number of Partnerships
  • 7.8. Analysis by Region
  • 7.9. Analysis by Country
  • 7.10. Intercontinental and Intracontinental Agreements

8. FUNDING AND INVESTMENTS

  • 8.1. Rare Kidney Disorders: List of Funding and Investments
  • 8.2. Cumulative Year-wise Trend of Funding, 2016 - 2022
  • 8.3. Analysis of Instances by Type of Funding
  • 8.4. Analysis of Instances by Type of Venture Funding
  • 8.5. Analysis of Instances by Year of Funding and Type of Funding
  • 8.6. Analysis by Type of Funding and Amount Invested
  • 8.7. Analysis of Instances by Type of Investor
  • 8.8. Analysis by Focus Area
  • 8.9. Analysis by Region
  • 8.11. Most Active Investors: Analysis by Number of Instances
  • 8.12. Most Active Players: Analysis by Number of Instances
  • 8.13. Most Active Players: Analysis by Amount Raised (USD Million)

9. CLINICAL TRIAL ANALYSIS

  • 9.1. Methodology and Parameters
  • 9.2. Cumulative Trend by Trial Registration Year, 2016 - 2022
  • 9.3. Analysis by Target Indication
  • 9.4. Analysis by Study Design
  • 9.5. Analysis by Region
  • 9.6. Analysis by Number of Trials, Phase of Development and Region
  • 9.7. Analysis by Patient Age
  • 9.8. Analysis by Trial Registration Year, Number of Trials and Region
  • 9.9. Analysis by Trial Status and Phase of Development
  • 9.10. Analysis of Patients Enrolled by Trial Registration Year
  • 9.11. Analysis of Patients Enrolled by Phase of Development
  • 9.12. Analysis by Number of Trials, Trial Status and Region
  • 9.13. Analysis of Patients Enrolled by Region
  • 9.14. Analysis of Patients Enrolled by Trial Status and Region

10. MARKET FORECAST

  • 10.1. Scope and Limitations
  • 10.2. Key Assumptions and Forecast Methodology
  • 10.3. Global Rare Kidney Disorders Market, 2022-2035
  • 10.4. Rare Kidney Disorders Market: Analysis by Type of Molecule, 2022-2035
    • 10.4.1. Rare Kidney Disorders Market for Biologics, 2022-2035
    • 10.4.2. Rare Kidney Disorders Market for Small Molecules, 2022-2035
  • 10.5. Rare Kidney Disorders Market: Analysis by Route of Administration, 2022-2035
    • 10.5.1. Rare Kidney Disorders Market for Oral Delivery, 2022-2035
    • 10.5.2. Rare Kidney Disorders Market for Intravenous Delivery, 2022-2035
    • 10.5.3. Rare Kidney Disorders Market for Subcutaneous Delivery, 2022-2035
    • 10.5.4. Rare Kidney Disorders Market for Other Delivery Routes, 2022-2035
  • 10.6. Rare Kidney Disorders Market: Analysis by Target Indication, 2022-2035
    • 10.6.1. Rare Kidney Disorders Market for Alport Syndrome, 2022-2035
    • 10.6.2. Rare Kidney Disorders Market for Atypical Hemolytic Uremic Syndrome, 2022-2035
    • 10.6.3. Rare Kidney Disorders Market for C3 Glomerulopathy, 2022-2035
    • 10.6.4. Rare Kidney Disorders Market for Cystinosis, 2022-2035
    • 10.6.5. Rare Kidney Disorders Market for Cystinuria, 2022-2035
    • 10.6.6. Rare Kidney Disorders Market for Dense Deposit Disease, 2022-2035
    • 10.6.7. Rare Kidney Disorders Market for Distal Renal Tubular Acidosis, 2022-2035
    • 10.6.8. Rare Kidney Disorders Market for Fabry Disease, 2022-2035
    • 10.6.9. Rare Kidney Disorders Market for IgA Nephropathy, 2022-2035
    • 10.6.10. Rare Kidney Disorders Market for Lupus Nephritis, 2022-2035
    • 10.6.11. Rare Kidney Disorders Market for Refractory Gout, 2022-2035
  • 10.7. Rare Kidney Disorders Market, 2022-2035: Analysis by Geography
    • 10.7.1. Rare Kidney Disorders Market in North America, 2022-2035
    • 10.7.2. Rare Kidney Disorders Market in Europe, 2022-2035
    • 10.7.3. Rare Kidney Disorders Market in Asia-Pacific, 2022-2035
    • 10.7.4. Rare Kidney Disorders Market in Rest of the World, 2022-2035

11. CLINICAL COMMERCIAL ATTRACTIVENESS

  • 11.1. Scope and Limitations
  • 11.2. Key Assumptions and Methodology
    • 11.3.1. Clinical and Commercial Attractiveness Analysis: Atypical Hemolytic Uremic Syndrome
    • 11.3.2. Clinical and Commercial Attractiveness Analysis: C3 Glomerulopathy
    • 11.3.3. Clinical and Commercial Attractiveness Analysis: Cystinuria
    • 11.3.4. Clinical and Commercial Attractiveness Analysis: Dense Deposit Disease
    • 11.3.5. Clinical and Commercial Attractiveness Analysis: Fabry Disease
    • 11.3.6. Clinical and Commercial Attractiveness Analysis: IgA Nephropathy
    • 11.3.7. Clinical and Commercial Attractiveness Analysis: Lupus Nephritis
    • 11.3.8. Clinical and Commercial Attractiveness Analysis: Refractory Gout
    • 11.3.9. Clinical and Commercial Attractiveness Analysis: Other Target Indications

12. CASE STUDY

  • 12.1. Scope and Key Parameters
  • 12.2. Rare Kidney Disorders: List of Kidney Care Providers
  • 12.3. Rare Kidney Disorders: Advantages of Kidney Care
  • 12.4. Rare Kidney Disorders: Future Perspectives
  • 12.5. Rare Kidney Disorders: Approach for Recent Initiatives

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

  • Table 3.1 Rare Kidney Disorders: List of Drugs
  • Table 4.1 Rare Kidney Disorders: List of Drugs
  • Table 4.2 Rare Kidney Disorders: List of Drug Developers
  • Table 5.1 Benlysta: Clinical Trial Information
  • Table 5.2 Cystadrops®: Clinical Trial Information
  • Table 5.3 Galafold®: Clinical Trial Information
  • Table 5.4 Tarpeyo®: Clinical Trial Information
  • Table 5.5 Ultomiris®: Clinical Trial Information
  • Table 5.6 Thiola®: Clinical Trial Information
  • Table 5.7 Lupkynis™: Clinical Trial Information
  • Table 5.8 Sibnayal™: Clinical Trial Information
  • Table 5.9 Pegunigalsidase Alfa: Clinical Trial Information
  • Table 5.10 Saphnelo™: Clinical Trial Information
  • Table 5.11 Atrasentan: Clinical Trial Information
  • Table 5.12 Bardoxolone Methyl: Clinical Trial Information
  • Table 5.13 Crovalimab: Clinical Trial Information
  • Table 5.14 Ianalumab: Clinical Trial Information
  • Table 5.15 Cozaar®: Clinical Trial Information
  • Table 5.16 Cosentyx®: Clinical Trial Information
  • Table 5.17 Empaveli®: Clinical Trial Information
  • Table 5.18 Rituxan®: Clinical Trial Information
  • Table 5.19 Sparsentan: Clinical Trial Information
  • Table 5.20 Iptacopan: Clinical Trial Information
  • Table 5.21 Narsoplimab: Clinical Trial Information
  • Table 7.1 Rare Kidney Disorders: List of Partnerships and Collaborations
  • Table 8.1 Rare Kidney Disorders: List of Funding and Investments
  • Table 12.1 Rare Kidney Disorders: List of Kidney Care Companies

LIST OF FIGURES

  • Figure 2.1 Rare Kidney Disorders: Executive Summary
  • Figure 3.1 Key Historical Events
  • Figure 3.2 Factors Contributing to Rare Kidney Disorders
  • Figure 3.3 Rare Kidney Disorders: Target Indications
  • Figure 3.4 Rare Kidney Disorders: Applications of Omics Technology
  • Figure 3.5 Rare Kidney Disorders: Future Outlook
  • Figure 4.1 Rare Kidney Disorders: Distribution by Stage of Development
  • Figure 4.2 Rare Kidney Disorders: Distribution by Target Molecule
  • Figure 4.3 Rare Kidney Disorders: Distribution by Type of Target Molecule and Route of Administration
  • Figure 4.4 Rare Kidney Disorders: Distribution by Target Indication
  • Figure 4.5 Rare Kidney Disorders: Distribution by Stage of Development and Target Indication
  • Figure 4.6 Rare Kidney Disorders: Distribution by Type of Target Molecule
  • Figure 4.7 Rare Kidney Disorders: Distribution by Stage of Development and Type of Target Molecule
  • Figure 4.8 Rare Kidney Disorders: Distribution by Year of Establishment
  • Figure 4.9 Rare Kidney Disorders: Distribution by Company Size
  • Figure 4.10 Rare Kidney Disorders: Distribution by Region
  • Figure 4.11 Most Active Players: Analysis by Number of Drugs
  • Figure 5.1 Benlysta: Estimated Sales Revenue
  • Figure 5.2 Cystadrops®: Estimated Sales Revenue
  • Figure 5.3 Galafold®: Estimated Sales Revenue
  • Figure 5.4 Tarpeyo®: Estimated Sales Revenue
  • Figure 5.5 Ultomiris®: Estimated Sales Revenue
  • Figure 5.6 Thiola®: Estimated Sales Revenue
  • Figure 5.7 Lupkynis™: Estimated Sales Revenue
  • Figure 5.8 Sibnayal™: Estimated Sales Revenue
  • Figure 5.9 Pegunigalsidase Alfa: Estimated Sales Revenue
  • Figure 5.10 Saphnelo™: Estimated Sales Revenue
  • Figure 5.11 Atrasentan: Estimated Sales Revenue
  • Figure 5.12 Bardoxolone Methyl: Estimated Sales Revenue
  • Figure 5.13 Crovalimab: Estimated Sales Revenue
  • Figure 5.14 Ianalumab: Estimated Sales Revenue
  • Figure 5.15 Cozaar®: Estimated Sales Revenue
  • Figure 5.16 Cosentyx®: Estimated Sales Revenue
  • Figure 5.17 Empaveli®: Estimated Sales Revenue
  • Figure 5.18 Rituxan®: Estimated Sales Revenue
  • Figure 5.19 Sparsentan: Estimated Sales Revenue
  • Figure 5.20 Iptacopan: Estimated Sales Revenue
  • Figure 5.21 Narsoplimab: Estimated Sales Revenue
  • Figure 6.1 Company Competitiveness Analysis (Peer Group I): Biologic Developers
  • Figure 6.2 Company Competitiveness Analysis (Peer Group II): Small Molecules Developers
  • Figure 7.1 Partnership Analysis: Distribution by Year of Partnership
  • Figure 7.2 Partnership Analysis: Distribution by Type of Partnership
  • Figure 7.3 Partnership Analysis: Distribution by Year and Type of Partnership
  • Figure 7.4 Partnership Analysis: Distribution by Type of Partnership and Company Size
  • Figure 7.5 Partnership Analysis: Distribution by Target Indication
  • Figure 7.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 7.7 Partnership Analysis: Regional Distribution
  • Figure 7.8 Partnership Analysis: Country-Wise Distribution
  • Figure 7.9 Partnership Analysis: Intercontinental and Intracontinental Agreements
  • Figure 8.1 Funding and Investments: Cumulative Distribution of Amount Invested by Year
  • Figure 8.2 Funding and Investments: Distribution of Instances by Type of Funding
  • Figure 8.3 Funding and Investments: Distribution of Instances by Type of Venture Funding
  • Figure 8.4 Funding and Investments: Distribution by Year and Type of Funding
  • Figure 8.5 Funding and Investments: Distribution of Instances by Type of Funding
  • Figure 8.6 Funding and Investments: Distribution of Instances by Type of Investor
  • Figure 8.7 Funding and Investments: Distribution by Amount Invested and Type of Molecule (USD Million)
  • Figure 8.8 Funding and Investments: Distribution by Focus Area
  • Figure 8.9 Funding and Investments: Distribution by Geography
  • Figure 8.10 Funding and Investments: Distribution by Amount Invested (USD Million) and Region (USD Million)
  • Figure 8.11 Most Active Investors: Analysis by Number of Instances
  • Figure 8.12 Most Active Players: Analysis by Number of Instances
  • Figure 8.13 Most Active Players: Analysis by Amount Raised (USD Million)
  • Figure 9.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
  • Figure 9.2 Clinical Trial Analysis: Distribution by Target Indication
  • Figure 9.3 Clinical Trial Analysis: Distribution by Study Design
  • Figure 9.4 Clinical Trial Analysis: Distribution by Region
  • Figure 9.5 Clinical Trial Analysis: Distribution by Number of Trials, Phase of Development and Region
  • Figure 9.6 Clinical Trial Analysis: Distribution by Patient Age
  • Figure 9.7 Clinical Trial Analysis: Distribution by Trial Registration Year, Number of Trials and Region
  • Figure 9.8 Clinical Trial Analysis: Distribution by Trial Status and Phase of Development
  • Figure 9.9 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year
  • Figure 9.10 Clinical Trial Analysis: Distribution of Patients Enrolled by Phase of Development
  • Figure 9.11 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
  • Figure 9.12 Clinical Trial Analysis: Patients Enrolled by Region
  • Figure 9.13 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Region
  • Figure 10.1 Global Rare Kidney Disorders Market, 2022-2035 (USD Million)
  • Figure 10.2 Rare Kidney Disorders Market: Distribution by Type of Molecule, 2022 and 2035
  • Figure 10.3 Rare Kidney Disorders Market for Biologics, 2022-2035 (USD Million)
  • Figure 10.4 Rare Kidney Disorders Market for Small Molecules, 2022-2035 (USD Million)
  • Figure 10.5 Rare Kidney Disorders Market: Distribution by Route of Administration, 2022 and 2035
  • Figure 10.6 Rare Kidney Disorders Market for Oral Delivery, 2022-2035 (USD Million)
  • Figure 10.7 Rare Kidney Disorders Market for Intravenous Delivery, 2022-2035 (USD Million)
  • Figure 10.8 Rare Kidney Disorders Market for Subcutaneous Delivery, 2022-2035 (USD Million)
  • Figure 10.9 Rare Kidney Disorders Market for Other Delivery Routes, 2022-2035 (USD Million)
  • Figure 10.10 Rare Kidney Disorders Market: Distribution by Target Indications, 2022 and 2035
  • Figure 10.11 Rare Kidney Disorders Market for Alport Syndrome, 2022-2035 (USD Million)
  • Figure 10.12 Rare Kidney Disorders Market for Atypical Hemolytic Uremic Syndrome, 2022-2035 (USD Million)
  • Figure 10.13 Rare Kidney Disorders Market for C3 Glomerulopathy, 2022-2035 (USD Million)
  • Figure 10.14 Rare Kidney Disorders Market for Cystinosis, 2022-2035 (USD Million)
  • Figure 10.15 Rare Kidney Disorders Market for Cystinuria, 2022-2035 (USD Million)
  • Figure 10.16 Rare Kidney Disorders Market for Dense Deposit Disease, 2022-2035 (USD Million)
  • Figure 10.17 Rare Kidney Disorders Market for distal Renal Tubular Acidosis, 2022-2035 (USD Million)
  • Figure 10.18 Rare Kidney Disorders Market for Fabry Disease, 2022-2035 (USD Million)
  • Figure 10.19 Rare Kidney Disorders Market for IgA Nephropathy, 2022-2035 (USD Million)
  • Figure 10.20 Rare Kidney Disorders Market for Lupus Nephritis, 2022-2035 (USD Million)
  • Figure 10.21 Rare Kidney Disorders Market for Refractory Gout, 2022-2035 (USD Million)
  • Figure 10.22 Rare Kidney Disorders Market: Distribution by Geography, 2022 and 2035
  • Figure 10.23 Rare Kidney Disorders Market in North America, 2022-2035 (USD Million)
  • Figure 10.24 Rare Kidney Disorders Market in Europe, 2022-2035 (USD Million)
  • Figure 10.25 Rare Kidney Disorders Market in Asia-Pacific, 2022-2035 (USD Million)
  • Figure 10.26 Rare Kidney Disorders Market in Rest of the World, 2022-2035 (USD Million)
  • Figure 11.1 Clinical and Commercial Attractiveness Analysis: Atypical Hemolytic Uremic Syndrome
  • Figure 11.2 Clinical and Commercial Attractiveness Analysis: C3 Glomerulopathy
  • Figure 11.3 Clinical and Commercial Attractiveness Analysis: Cystinuria
  • Figure 11.4 Clinical and Commercial Attractiveness Analysis: Dense Deposit Disease
  • Figure 11.5 Clinical and Commercial Attractiveness Analysis: Fabry Disease
  • Figure 11.6 Clinical and Commercial Attractiveness Analysis: IgA Nephropathy
  • Figure 11.7 Clinical and Commercial Attractiveness Analysis: Lupus Nephritis
  • Figure 11.8 Clinical and Commercial Attractiveness Analysis: Refractory Gout
  • Figure 11.9 Clinical and Commercial Attractiveness Analysis: Other Target Indications